A Phase 4 interventional study of NVA237 and Tiotropium in Chronic Obstructive Pulmonary Disease, sponsored by Novartis Pharmaceuticals. Completed at 14 sites in Germany. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2015-01-01.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 37th largest by enrollment, is one of 5 that started in 2013, is one of 11 in phase 4, and was the 35th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
By country, each count listing its studies:
Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 21 · Phase 3 33 · Phase 4 11
First in 2005; this study’s year is marked. 5 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 152 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 152 across the 73 interventional studies. Of the 67 that completed or were terminated, 49 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 73 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
117 studies in Pulmonary Disease, Chronic Obstructive by Novartis: none open now, none under way, none of them phase 3. Of 110 finished, 94 (85%) have results posted.
Among the 117 studies in Pulmonary Disease, Chronic Obstructive by Novartis, this one is the 66th largest by enrollment of the 116 interventional ones that give a count, is one of 10 that started in 2013, is one of 24 in phase 4, and was the 90th registered.
Novartis’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2003.
1 of the studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 117 in Pulmonary Disease, Chronic Obstructive:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to further figure out differences of glycopyrronium bromide compared to tiotropium in early bronchodilation measured by a comprehensive assessment of lung function that includes hyperinflation and specific airway resistance in patients with moderate to severe COPD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: NVA237 plus placebo to tiotropium on day 1, followed by a 7 day washout. Period 2: tiotropium plus placebo to NVA237 on day 8. Salbutamol was used as rescue medication.
Drug: NVA237 · Drug: Tiotropium · Drug: Placebo to tiotropium · Drug: Salbutamol
Period 1: tiotropium plus placebo to NVA237 on day 1, followed by a 7 day washout. Period 2: NVA237 plus placebo to tiotropium on day 8. Salbutamol was used as rescue medication.
Drug: Placebo to NVA237 · Drug: Salbutamol
NVA237 44 µg inhalation capsules once daily, delivered via single-dose dry-powder inhaler (SDDPI)
Tiotropium 18 μg once daily delivered via HandiHaler® device.
Placebo to NVA237 once daily, delivered via single-dose dry-powder inhaler (SDDPI).
Placebo to tiotropium once daily delivered via HandiHaler® device
Used as resuce medication
Forced Expiratory Volume in One Second (FEV1) Area Under Curve (AUC) 0-2
Standardized Forced Expiratory Volume in One Second (FEV1) AUC0-2h will be measured via spirometry. The AUC will be calculated from the FEV1 measurements obtained at timepoints between 0 min and 2h using the trapezoidal rule and will be standardized (=divided) by the measurement time (i.e. 2h).
Time frame: Day 1
Forced Expiratory Volume in One Second (FEV1) 15 Min Post Dose
Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. FEV1 will be measured by spirometry. All spirometry calibrations and evaluations will follow the recommendations of the American Thoracic Society / European Respiratory Society guidelines for acceptability.
Time frame: Day 1
Specific Airway Resistance (sRAW)
Specific Airway Resistance (sRAW) indicates volume and resistance-dependent work of breathing needed in order to generate a reference flow rate of 1 L/s, measured by kPa\*s. Whole body plethysmography (Bodybox) is used to measure SRaw.
Time frame: Day 1
Functional Resistance Capacity (FRCpleth)
Functional Resistance Capacity (FRCpleth) will be measured using whole body plethysmography (Bodybox).
Time frame: Day 1
Residual Volume (RV)
Residual Volume (RV) will be measured using whole body plethysmography (Bodybox).
Time frame: Day 1
Total Lung Capacity (TLC)
Total Lung Capacity (TLC) is the best vital capacity plus residual volume (RV). Whole body plethysmography (Bodybox) will be used to measure TLC.
Time frame: Day 1
Inspiratory Capacity (IC)
Inspiratory Capacity (IC) is the volume of air breathed in by a maximum inspiration at the end of a normal expiration. Whole body plethysmography (Bodybox) will be used to measure IC.
Time frame: Day 1
| Milestone | NVA237 Followed by Tiotropium | Tiotropium Followed by NVA237 |
|---|---|---|
| Started | 76 | 76 |
| Completed | 76 | 76 |
| Not completed | 0 | 0 |
| Milestone | NVA237 Followed by Tiotropium | Tiotropium Followed by NVA237 |
|---|---|---|
| Started | 76 | 76 |
| Completed | 75 | 76 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Milestone | NVA237 Followed by Tiotropium | Tiotropium Followed by NVA237 |
|---|---|---|
| Started | 75 | 76 |
| Completed | 75 | 76 |
| Not completed | 0 | 0 |
Standardized Forced Expiratory Volume in One Second (FEV1) AUC0-2h will be measured via spirometry. The AUC will be calculated from the FEV1 measurements obtained at timepoints between 0 min and 2h using the trapezoidal rule and will be standardized (=divided) by the measurement time (i.e. 2h).
| liters per hour | NVA237 | Tiotropium |
|---|---|---|
| Forced Expiratory Volume in One Second (FEV1) Area Under Curve (AUC) 0-2 | 1.490 ± 0.4232 | 1.453 ± 0.4135 |
Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. FEV1 will be measured by spirometry. All spirometry calibrations and evaluations will follow the recommendations of the American Thoracic Society / European Respiratory Society guidelines for acceptability.
| liters per hour | NVA237 | Tiotropium |
|---|---|---|
| Forced Expiratory Volume in One Second (FEV1) 15 Min Post Dose | 1.433 ± 0.4110 | 1.398 ± 0.4092 |
Specific Airway Resistance (sRAW) indicates volume and resistance-dependent work of breathing needed in order to generate a reference flow rate of 1 L/s, measured by kPa\*s. Whole body plethysmography (Bodybox) is used to measure SRaw.
| kilopascal (kPa) | NVA237 | Tiotropium |
|---|---|---|
| -45 min (n=152, 150) | 4.203 ± 1.8102 | 4.105 ± 1.8338 |
| 30 min (n=150, 151) | 2.904 ± 1.4759 | 3.089 ± 1.4555 |
| 1 hr (n=151, 149) | 2.656 ± 1.3062 | 2.877 ± 1.4130 |
| 1 hr 30 min (n=151, 150) | 2.632 ± 1.3152 | 2.811 ± 1.4065 |
| 2 hr 30 min (n=150, 149) | 2.643 ± 1.3146 | 2.756 ± 1.4091 |
| 3 hr 30 min (n=150, 149) | 2.779 ± 1.4496 | 2.828 ± 1.4534 |
Functional Resistance Capacity (FRCpleth) will be measured using whole body plethysmography (Bodybox).
| Liters | NVA237 | Tiotropium |
|---|---|---|
| -45 min (n=152, 150) | 5.211 ± 1.3086 | 5.142 ± 1.2656 |
| 30 min (n=150, 151) | 4.823 ± 1.2517 | 4.852 ± 1.1812 |
| 1 hr (n=151, 149) | 4.769 ± 1.2571 | 4.725 ± 1.1496 |
| 1 hr 30 min (n=151, 149) | 4.756 ± 1.2366 | 4.714 ± 1.1523 |
| 2 h 30 min (n= 150, 149) | 4.736 ± 1.1545 | 4.676 ± 1.2243 |
| 3 h 30 min (n= 150, 148) | 4.761 ± 1.2286 | 4.704 ± 1.1911 |
Residual Volume (RV) will be measured using whole body plethysmography (Bodybox).
| Liters | NVA237 | Tiotropium |
|---|---|---|
| -45 min (n=152, 150) | 4.433 ± 1.2596 | 4.344 ± 1.1707 |
| 30 min (n=150, 151) | 3.996 ± 1.1862 | 4.035 ± 1.0689 |
| 1 hr (n=151, 149) | 3.891 ± 1.1997 | 3.913 ± 1.0281 |
| 1 hr 30 min (n=151, 149) | 3.910 ± 1.1534 | 3.903 ± 1.0281 |
| 2 h 30 min (n= 150, 149) | 3.893 ± 1.0486 | 3.861 ± 1.1058 |
| 3 h 30 min (n= 150, 148) | 3.970 ± 1.1576 | 3.895 ± 1.0740 |
Total Lung Capacity (TLC) is the best vital capacity plus residual volume (RV). Whole body plethysmography (Bodybox) will be used to measure TLC.
| Liters | NVA237 | Tiotropium |
|---|---|---|
| -45 min (n=152, 150) | 7.380 ± 1.4781 | 7.335 ± 1.4328 |
| 30 min (n=150, 151) | 7.255 ± 1.4628 | 7.274 ± 1.4032 |
| 1hr (n=151, 149) | 7.224 ± 1.4294 | 7.161 ± 1.4015 |
| 1hr 30 min (n=151, 149) | 7.227 ± 1.4383 | 7.165 ± 1.3690 |
| 2hr 30 min (n=150, 149) | 7.203 ± 1.3700 | 7.149 ± 1.4476 |
| 3hr 30 min (n=150, 148) | 7.240 ± 1.4297 | 7.149 ± 1.3963 |
Inspiratory Capacity (IC) is the volume of air breathed in by a maximum inspiration at the end of a normal expiration. Whole body plethysmography (Bodybox) will be used to measure IC.
| Liters | NVA237 | Tiotropium |
|---|---|---|
| -45 min (n=152, 150) | 2.169 ± 0.5548 | 2.193 ± 0.5583 |
| 30 min (n=150, 151) | 2.433 ± 0.5934 | 2.422 ± 0.5996 |
| 1hr (n=151, 149) | 2.455 ± 0.6001 | 2.435 ± 0.5908 |
| 1hr 30 min (n=151, 150) | 2.472 ± 0.6200 | 2.457 ± 0.5883 |
| 2hr 30 min (n=150, 149) | 2.467 ± 0.5929 | 2.474 ± 0.6051 |
| 3hr 30 min (n=150, 149) | 2.479 ± 0.6036 | 2.449 ± 0.5907 |
Non-serious events are listed at a 0.5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NVA237 | — | 2/152 (1.3%) | 8/152 (5.3%) |
| Tiotropium | — | 2/151 (1.3%) | 15/151 (9.9%) |
| Event | NVA237 | Tiotropium |
|---|---|---|
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/152 | 1/151 |
| NephrectomySurgical and medical procedures | 0/152 | 1/151 |
| Acute myocardial infarctionCardiac disorders | 1/152 | 0/151 |
| Myocardial infarctionCardiac disorders | 1/152 | 0/151 |
| Event | NVA237 | Tiotropium |
|---|---|---|
| NasopharyngitisInfections and infestations | 3/152 | 4/151 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/152 | 3/151 |
| RhinitisInfections and infestations | 0/152 | 2/151 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/152 | 2/151 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/152 | 0/151 |
| ContusionInjury, poisoning and procedural complications | 0/152 | 1/151 |
| Electrocardiogram QT prolongedInvestigations | 0/152 | 1/151 |
| Back painMusculoskeletal and connective tissue disorders | 0/152 | 1/151 |
| HeadacheNervous system disorders | 1/152 | 1/151 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 0/152 | 1/151 |
| Age, Continuous(years) | NVA237 Followed by Tiotropium | Tiotropium Followed by NVA237 | Total |
|---|---|---|---|
| Mean | 61.9 ± 7.2 | 61.7 ± 8.2 | 61.8 ± 7.7 |
| Sex: Female, Male(Participants) | NVA237 Followed by Tiotropium | Tiotropium Followed by NVA237 | Total |
|---|---|---|---|
| Female | 28 | 26 | 54 |
| Male | 48 | 50 | 98 |
The record gives a start of Aug 2013, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2015, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glycopyrrolate
Pulmonary Disease, Chronic Obstructive →